| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
| ln Vitro |
Hemoglobin, mean corpuscular volume, serum iron, ferritin, and percent iron saturation all rise significantly after intravenous iron sucrose injection, whereas total iron binding capacity falls in tandem [1]. According to in vitro survival experiments, 40–80% of exponentially developing colon cancer cell lines (HCT116 and HT29) experienced clonal inactivation following a 2-hour exposure to 10 mM ascorbic acid. In comparison to pharmacological ascorbic acid alone, colon cancer cells treated with or without 250 µM sucrose iron showed higher amounts of labile iron after being rinsed and treated with 10 mM ascorbic acid. This led to a considerable increase in clonal cell death. 2]. through the activation of NF-κB signaling and NADPH oxidase (NOx) in human aortic endothelial cells treated with sucrose iron. Within 1 to 3 hours, HAECs produced more intracellular ROS at a concentration of 160 μg/mL due to the considerable time-dependent increase in ROS production, which lessened by 4 hours [3].
|
|---|---|
| ln Vivo |
In subtotal nephrectomized animals, iron sucrose markedly boosted tissue superoxide generation, tissue cell adhesion molecule expression, and endothelium adhesion. In uninephrectomized ApoE-/-mice, iron sucrose exacerbates atherosclerosis in the aorta [3].
|
| References |
|
| Additional Infomation |
A glucaric acid-iron conjugate that is used in the treatment of IRON-DEFICIENCY ANEMIA, including in patients with chronic kidney disease, when oral iron therapy is ineffective or impractical.
|
| Molecular Formula |
C18H24FE2O24
|
|---|---|
| Molecular Weight |
736.06
|
| Exact Mass |
735.935
|
| CAS # |
8047-67-4
|
| PubChem CID |
11377634
|
| Appearance |
Brown to black solid powder
|
| Boiling Point |
766.4ºC at 760 mmHg
|
| Melting Point |
MORE THAN 51ºC
|
| Flash Point |
431.2ºC
|
| Hydrogen Bond Donor Count |
12
|
| Hydrogen Bond Acceptor Count |
24
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
44
|
| Complexity |
191
|
| Defined Atom Stereocenter Count |
12
|
| SMILES |
[C@H]([C@@H]([C@@H](C(=O)[O-])O)O)([C@H](C(=O)[O-])O)O.[C@H]([C@@H]([C@@H](C(=O)[O-])O)O)([C@H](C(=O)[O-])O)O.[C@H]([C@@H]([C@@H](C(=O)[O-])O)O)([C@H](C(=O)[O-])O)O.[Fe+3].[Fe+3]
|
| InChi Key |
ADQSUDSYBZBMFT-GFPJEPEZSA-H
|
| InChi Code |
InChI=1S/3C6H10O8.2Fe/c3*7-1(3(9)5(11)12)2(8)4(10)6(13)14;;/h3*1-4,7-10H,(H,11,12)(H,13,14);;/q;;;2*+3/p-6/t3*1-,2-,3-,4+;;/m000../s1
|
| Chemical Name |
iron(3+);(2S,3S,4S,5R)-2,3,4,5-tetrahydroxyhexanedioate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~7.14 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.71 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 7.1 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3586 mL | 6.7929 mL | 13.5858 mL | |
| 5 mM | 0.2717 mL | 1.3586 mL | 2.7172 mL | |
| 10 mM | 0.1359 mL | 0.6793 mL | 1.3586 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
